849668-91-3

Basic information

• Product Name: BenzaMide, 2-aMino-N-[4-[2-(3,4-dihydro-6,7-diMethoxy-2(1H)-isoquinolinyl)ethyl]phenyl]-4,5-diMethoxy-
• Synonyms: BenzaMide, 2-aMino-N-[4-[2-(3,4-dihydro-6,7-diMethoxy-2(1H)-isoquinolinyl)ethyl]phenyl]-4,5-diMethoxy-;2-AMino-N-[4-[2-(6,7-diMethoxy-3,4-dihydro-1H-isoquinolin-2-yl)ethyl]phenyl]-4,5-diMethoxybenzaMide
• CAS NO: 849668-91-3
• Molecular Formula: C₂₈H₃₃N₃O₅
• Molecular Weight: 491.57872
• Mol File: 849668-91-3.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• Storage Temp.: Refrigerator
• Solubility: DMSO (Slightly), Methanol (Slightly)
• CAS DataBase Reference: BenzaMide, 2-aMino-N-[4-[2-(3,4-dihydro-6,7-diMethoxy-2(1H)-isoquinolinyl)ethyl]phenyl]-4,5-diMethoxy-(CAS DataBase Reference)
• NIST Chemistry Reference: BenzaMide, 2-aMino-N-[4-[2-(3,4-dihydro-6,7-diMethoxy-2(1H)-isoquinolinyl)ethyl]phenyl]-4,5-diMethoxy-(849668-91-3)
• EPA Substance Registry System: BenzaMide, 2-aMino-N-[4-[2-(3,4-dihydro-6,7-diMethoxy-2(1H)-isoquinolinyl)ethyl]phenyl]-4,5-diMethoxy-(849668-91-3)

Safety Data

• Hazardous Substances Data: 849668-91-3(Hazardous Substances Data)

Usage

Uses

2-Amino-N-[4-[2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)ethyl]phenyl]-4,5-dimethoxybenzamide is an intermediate in the synthesis of Tariquidar (T007600), a P-glycoprotein drug efflux pump inhibitor that is potentially used in cancer patients.

Upstream product

• 1024592-54-8 N-{4-[2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-ethyl]-phenyl}-4,5-dimethoxy-2-nitro-benzamide 
• 4998-07-6 4,5-dimethoxy-2-nitro-benzoic acid 
• 29568-78-3 4,5-dimethoxy-2-nitrobenzoyl chloride 
• 1745-07-9 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline 
• 5339-26-4 (4-nitrophenyl)ethyl bromide 
• 82925-01-7 1,2,3,4-Tetrahydro-6,7-dimethoxy-2-[2-(4-nitrophenyl)ethyl]-isoquinoline 
• 82925-02-8 4-<2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolyl)ethyl>benzenamine 

Downstream Products

• 206873-63-4 tariquidar 

Relevant articles and documents

DEUTERATED ANALOGS OF TARIQUIDAR

The present invention relates to efflux inhibitor compounds, compositions, and methods of using the same. More specifically, the instant invention comprises deuterated analogs of tariquidar with superior pharmacokinetic properties such that it is now poss

NOVEL P-GLYCOPROTEIN INHIBITOR, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

A p-glycoprotein inhibitor of Formula 1 is capable of effectively preventing the development of multi-drug resistance directed to an anticancer agent in cancer cells, and greatly enhances the bioavailability of the drug, such as paclitaxel, which is not readily absorbed when orally administered.